Lavestra H

Losartan potassium and hydrochlorothiazide, the active ingredient in Lavestra H, is an angiotensin II receptor blocker and thiazide diuretic presented as an oral tablet for systemic use. It is indicated for the management of hypertension and for reducing fluid overload in adults. GNH USA supplies Lavestra H as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lavestra H combines an angiotensin II receptor blocker with a thiazide diuretic to lower elevated blood pressure and reduce excess fluid. - Hypertension: lowers systolic and diastolic pressure in patients with primary hypertension. - Edema: promotes diuresis to relieve fluid accumulation associated with congestive states. - Cardiovascular risk reduction: contributes to long‑term risk management when used as part of a comprehensive antihypertensive regimen.

Lavestra H may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness or light‑headedness - Headache - Increased urination or nocturia - Electrolyte disturbances such as low potassium - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Hyperkalemia or significant potassium loss - Acute kidney injury or worsening renal function - Angioedema or severe allergic reaction - Marked hypotension leading to syncope

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor relevant parameters. - Blood pressure monitoring: ensure adequate control without excessive hypotension. - Electrolyte assessment: check potassium and sodium levels regularly. - Renal function: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Pregnancy: avoid use in pregnancy due to fetal risk (Category D). - Concomitant NSAIDs: use with caution as they may impair renal function. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lavestra H can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalemia. - Potassium supplements or high‑potassium diets: may precipitate hyperkalemia. - ACE inhibitors or other ARBs: additive effects on potassium and renal function.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy and affect renal clearance. - Lithium: increased lithium levels, risk of toxicity. - CYP2C9 inhibitors (e.g., fluconazole): may raise losartan plasma concentrations.